<p><strong>Hepatic Impairment</strong>: No dose adjustment is required in patients with mild hepatic impairment. Because patients with moderate hepatic impairment may have intrinsic coagulation abnormalities and there is limited clinical experience with Apixaban in these patients, dosing recommendations cannot be provided Apixaban is not recommended in patients with severe hepatic impairment<br />
<br />
<strong>Renal Impairment</strong>: The dosing adjustment for moderate renal impairment is described above. No data inform use in patients with creatinine clearance &lt;15 ml/min or on dialysis.<br />
<br />
<strong>Pediatric Use</strong>: Safety and effectiveness in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Of the total subjects in clinical studies of Apixaban, &gt;69% were 65 and older, and &gt;31% were 75 and older. The effects of Apixaban on the risk of stroke and major bleeding compared to warfarin were maintained in geriatric subjects.</p>